Multiple Sclerosis Research Studies

Dr. Gary Birnbaum, retired MCN MS specialist, offers updates about Multiple Sclerosis research on his new blog:  www.MSResearchUpdate.com

WA21092 (“Opera”)

Study Overview

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif ®) In Patients with Relapsing Multiple Sclerosis

Study Duration–96 Weeks

Phase-III

Enrollment Closed

Principal Investigator

Jessica Stulc, MD

Sponsor

F.Hoffmann-La Roche Ltd

Research Contact

If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.

109MS401 (“ESTEEM”)

Study Overview

A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis.

Principal Investigator

Jessica Stulc, MD

Sponsor

Biogen Idec

Research Contact

If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.

Protocol No.:  CLR_09_21

Study Overview

A Placebo-Controlled Randomized Withdrawal Evaluation of the Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects with Spasticity Due to Multiple Sclerosis.

Principal Investigator

Jessica Stulc, MD

Sponsor

Sun Pharmaceuticals

Research Contact

If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.

105MS401 (“POP”)

Study Overview

Plegridy™ (peginterferon β 1a) Real World Effectiveness and Safety Observational Program.

Principal Investigator

Jessica Stulc, MD

Sponsor

Biogen Idec

Research Contact

If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.

TV5600-CNS-200006: ARPEGGIO 

Study Overview

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients with Primary Progressive Multiple Sclerosis.

Principal Investigator

Jessica Stulc, MD

Sponsor

Teva Pharmaceuticals

Research Contact

If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.

TV44400-CNS-40083 (CONFIDENCE)

Study Overview

A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous Injections of Copaxone® (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily.

Principal Investigator

Jessica Stulc, MD

Research Contact

If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.

Alkermes ALK8700-A301 (EVOLVE)

Study Overview

A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis.

Principal Investigator

Jessica Stulc, MD

Research Contact

If interested please contact Dr. Stulc’s Clinical Research Coordinator at 763-302-4072.